⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PVLA News
Palvella Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
PVLA
Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com
PVLA
Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing
globenewswire.com
PVLA
Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026
globenewswire.com
PVLA
Form 8-K
sec.gov
PVLA
Form 8-K
sec.gov
PVLA
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
globenewswire.com
SVRA
SLNO
INSM
PVLA
PTHS
Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
globenewswire.com
PVLA
FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations
globenewswire.com
PVLA
Form 8-K
sec.gov
PVLA